ACADIA Pharmaceuticals (FRA:DR6) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DR6 ACADIA Pharmaceuticals Inc FRA:DR6
80 GF Score
Price €23.80
GF Value €21.71
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ACADIA Pharmaceuticals  (FRA:DR6) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.21 4.60 8.29 4.53 4.95

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.32 5.52 5.40 4.86 5.66

FRA:DR6 vs PBLS, DYN, EWTX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:DR6
80GF Score
ACADIA Pharmaceuticals Inc FRA:DR6
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, ACADIA Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.639/333.9520*333.9520
=6.639

Current CPI (Jun. 2026) = 333.9520.

ACADIA Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 4.247 241.428 5.875
201612 4.050 241.432 5.602
201703 3.507 243.801 4.804
201706 2.975 244.955 4.056
201709 2.601 246.819 3.519
201712 2.244 246.524 3.040
201803 1.982 249.554 2.652
201806 1.814 251.989 2.404
201809 1.539 252.439 2.036
201812 2.913 251.233 3.872
201903 2.585 254.202 3.396
201906 2.364 256.143 3.082
201909 4.118 256.759 5.356
201912 4.011 256.974 5.213
202003 3.743 258.115 4.843
202006 3.751 257.797 4.859
202009 3.515 260.280 4.510
202012 3.210 260.474 4.116
202103 3.090 264.877 3.896
202106 2.965 271.696 3.644
202109 3.044 274.310 3.706
202112 2.954 278.802 3.538
202203 2.477 287.504 2.877
202206 2.570 296.311 2.896
202209 2.684 296.808 3.020
202212 2.315 296.797 2.605
202303 2.121 301.836 2.347
202306 2.221 305.109 2.431
202309 2.086 307.789 2.263
202312 2.374 306.746 2.585
202403 2.605 312.332 2.785
202406 2.907 314.175 3.090
202409 3.109 315.301 3.293
202412 4.245 315.605 4.492
202503 4.239 319.799 4.427
202506 4.155 322.561 4.302
202509 4.615 324.800 4.745
202512 6.136 324.054 6.323
202603 6.331 330.213 6.403
202606 6.639 333.952 6.639

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of €23.80 is trading 9.6% above its estimated GF Value™ of €21.71. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:DR6:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €21.71 vs. price of €23.80 (9.6% above fair value)
  • GF Score™: 80/100 with 10 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USAACAD:Mexico
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
80GF Score

Get the complete analysis for FRA:DR6

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.80
Price
€21.71
GF Value